Preventing Depression And Reducing The Impact Of Aphasia In Stroke Patients And Their Caregivers A Year Post Onset Via A Brief Early Intervention: A Cluster Randomised Control Trial Of The Action Success Knowledge (ASK) Program.
Funder
National Health and Medical Research Council
Funding Amount
$1,327,820.00
Summary
Loss of language after stroke (aphasia) leads to problems with understanding, talking, reading and writing. Aphasia often leads to depression and poorer wellbeing for the person with aphasia and the caregiver. Our research has a) identified what it takes to live successfully with aphasia, b) translated the results to a program called ASK, and c) piloted ASK with promising outcomes in reducing symptoms of depression. We will measure the impact of ASK at 12 month post stroke.
Phosphonated Calixarenes For The Targeted Intracellular Delivery Of Anticancer Agents
Funder
National Health and Medical Research Council
Funding Amount
$322,267.00
Summary
Many anticancer drugs have severe side effects due to their potency and non-specificity of action. To improve the treatment outcome for thousands of cancer patients, we aim to engineer calixarene-based nanocarriers that bypass normal tissues to selectively deposit drugs and imaging agents into tumour cells. Such delivery systems will optimize the performance of a host of anticancer agents that act within cells, and enable drug treatment and monitoring to be simultaneously realised.
Influence Of Skin Cancer On Topical Elongate Microparticle Drug Delivery
Funder
National Health and Medical Research Council
Funding Amount
$560,589.00
Summary
This project builds on a novel cutaneous delivery method using ‘rod-shaped’ microparticles we developed in the Dermatology Research Centre. Microparticle administration results in multiple punctures of the skin’s tough outer layers, increasing permeability. Furthermore, microparticle administration results in a uniform and continuous drug delivery profile within the treatment area, which is an important attribute for the treatment of skin diseases.
Improving Therapeutic Delivery By Understanding Nanoparticle Interactions With Cells
Funder
National Health and Medical Research Council
Funding Amount
$553,152.00
Summary
Nanotechnology has the potential to transform the way we treat many diseases. This project will investigate how nanoengineered particles can be used to improve the effectiveness of vaccines. Nanoparticles can protect the delicate vaccine cargo from degradation, and will be targeted specifically to the cells in the body that most effectively induce the maximum theraputic response. This study will improve our understanding of how nanovaccines work and develop new ways of delivering vaccines.
Novel Inhalation Formulation Of Colistin And Combination Therapy Against Gram-negative 'superbugs'
Funder
National Health and Medical Research Council
Funding Amount
$513,896.00
Summary
Respiratory infections caused by multidrug-resistant Gram-negative bacteria are major health problems for Australians. Colistin is the last-resort defense in most cases. However, parenteral administration of colistin will cause serious side effects. This proposal applies an interdisciplinary approach using aerosol particle engineering, functional lung imaging and antimicrobial pharmacology to develop and characterise novel inhaled powder formulations of colistin and its rational combinations.
Novel Inhalation Formulation Of Bacteriophages Against ‘superbugs’ Causing Respiratory Infections
Funder
National Health and Medical Research Council
Funding Amount
$563,621.00
Summary
Emergence of superbugs has led to life-threatening respiratory infections that are resistant to most antibiotics. There is an urgent need for alternative treatments not relying on antibiotics. Bacteriophages (or ‘bacteria eaters’) are natural predators of bacteria and are unaffected by antibiotic resistance. This multi-disciplinary project will develop novel therapeutics using inhaled bacteriophages against bacterial infections in the lungs.
Most adults will have already sustained damage to the tiny connections between hearing cells and nerve cells; a missing link in their auditory pathway. There is no way to repair the damage and our hearing will worsen over time. We now have compelling evidence that a growth factor therapy to the inner ear restores the connections. We will deliver world-first data to justify and set the parameters for a clinical trial for a therapy to treat hearing loss for the first time.
Simultaneous Imaging And Drug Delivery For Prostate Cancer Theranostics
Funder
National Health and Medical Research Council
Funding Amount
$565,205.00
Summary
Prostate cancer (PC) is the most common cancer in men over 50. The answers to the key questions in advanced PC (Who to treat, and how to treat: loco-regionally or systemically?) rest with clinical staging – something that has hitherto been very imprecise. We have generated a highly-sensitive 19F-molecular imaging agent which could help resolve both questions and create a targeted therapy, diminishing the burden of harm of today’s therapies by using nanoparticles to diagnose and treat PC.
A Novel Intervention Targeting Insomnia To Prevent Major Depressive Disorder In The Community
Funder
National Health and Medical Research Council
Funding Amount
$1,258,316.00
Summary
In this project we want to see if we can prevent depression by improving insomnia. We will invite people with elevated depression symptoms to undertake a novel self help program to reduce insomnia, and then see if their risk for developing clinical depression is reduced 9 and 18 months later. As far as we know, this approach has not previously been tried. The merit of the project is that we have tangible symptoms (sleep problems) with which to engage individuals in a prevention strategy.
A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$560,659.00
Summary
New drugs for cancer therapy are essential to develop that overcome resistance to standard chemotherapeutics. We have developed potent anti-cancer chelators that bind to the abundant plasma protein, albumin. Our studies showed increased tumour cell uptake of the chelator, Dp44mT, mediated by albumin. We will elucidate the mechanisms of their albumin-mediated uptake, with the aim to implement albumin nanoparticles as carriers of novel chelators to selectively target tumours.